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The kidneys play an important role in maintaining the
acid-base balance, as they excrete hydrogen ions and re-
generate bicarbonate, thereby regulating intra- as well
as extracellular pH, which are vital for normal cell func-
tion. In patients with renal failure, the inability of the
kidneys to excrete an excess of hydrogen ions results in
metabolic acidosis due to retention of acid degradation
products, which has a detrimental effect on protein as well
as amino acid turnover and leads to hypercatabolism [1].
In these patients, treatment with bicarbonate has been
shown to improve nitrogen balance and decrease both
whole body amino acid oxidation and protein degrada-
tion [2]. Metabolic acidosis also negatively affects car-
diac, as well as bone, function. Consequently, one of the
most important objectives of any dialysis therapy, includ-
ing peritoneal dialysis (PD), is to correct acidosis. The
correction of acidosis in PD is generally more stable than
what can be achieved with intermittent hemodialysis [3],
and this may be one of the most important advantages of
PD compared to hemodialysis. Historically, bicarbonate
was the first buffer used in PD to correct uremic acidosis.
However, the use of this buffer was soon discontinued
due to its poor stability in the PD solution [4]. In a search
for alternative buffering agents, bicarbonate was replaced
by either lactate or acetate. Both buffers maintain effec-
tive acid-base balance as they react with hydrogen ions
derived from carbonic acid, thereby regenerating bicar-
bonate. Acetate, however, was subsequently found to be
associated with loss of ultrafiltration and sclerosing peri-
tonitis [5]. Its use was abandoned in the 1980s, leaving
lactate as the only buffer used in PD for many years.
A high lactate concentration is required to correct aci-
dosis and the solution must be formulated at low pH
to prevent caramelization of glucose during routine heat
sterilization. As a result, these solutions have the poten-
tial for impairing peritoneal function and cause infusion
pain during dialysis [6, 7]. Several solution components
are thought to play a role in the modulation of peritoneal
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cell function, peritoneal host defense, and the develop-
ment of structural alterations in the dialyzed peritoneal
membrane. These factors include solution pH, lactate
concentration, as well as the concentration of glucose and
glucose degradation products (GDP) in the solution [8].
Therefore, alternative solutions with a more physiologic
buffer system would represent a major evolution in PD
therapy. One alternative is to use the body’s major natu-
ral buffer, bicarbonate. Because for acidosis correction,
a supraphysiologic bicarbonate level would be necessary,
this level would also be associated with a supranormal
level of dissolved carbon dioxide (pCO2). Although the
clinical impact of higher than physiologic levels of bicar-
bonate and pCO2 is unknown, recent evidence has indi-
cated that elevated pCO2 levels may have undesired side
effects [8]. It was suggested, therefore, that a combination
of a physiologic bicarbonate concentration (25 mmol/L)
and a lower lactate concentration (15 mmol/L) (B/L 25/15
solution, registered as Physioneal) might have the dual
benefit of adequately correcting acidosis and improving
the biocompatibility profile of the solution, and thus be
preferred over a pure bicarbonate solution. The pCO2 of
this B/L 25/15 formulation is at the physiologic level and
is therefore considered safe [8–10]. Indeed, in a compari-
son between a pure bicarbonate formulation (38 mmol/L)
and the B/L 25/15 formulation was found to have supe-
rior effects, both in vitro, ex vivo [11, 12], as well as in a
phase II clinical trial [9, 10].
The B/L solutions are contained in a two-chambered
bag, which overcomes many of the problems associated
with the use of pure bicarbonate or conventional lactate-
buffered PD solutions. The primary advantages of the
B/L solution are: (1) a physiologic pH and pCO2; (2) a
buffer that is physiologic in nature and at a physiologic
concentration; (3) reduced GDPs; and (4) reduced lactate
concentration. Thus, the B/L solution represents an effec-
tive, safe, well-tolerated, and physiologically balanced al-
ternative to conventional lactate-buffered PD solutions.
Because there is now an increasing cumulative clinical
experience with the use of B/L solutions, the aim of the
present review is to summarize the findings of the most
important clinical studies that provide support for the use
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of this alternative dialysis solution as a standard solution
for PD treatment in the near future.
CLINICAL EXPERIENCE WITH B/L SOLUTIONS
Since the introduction of B/L solutions, increasing clini-
cal experience has been accumulated, consisting of a wide
variety of studies, from in vitro to ex vivo and in vivo
studies, and randomized clinical trials to registry reports.
In the following section, a summary of the most impor-
tant clinical studies that analyzed this PD solution will
be presented, concentrating on its effects on acid-basis
status, fluid balance, small solute clearances, biocompat-
ibility markers, and infusion pain. The last section of this
review will provide an overview of the safety profile of
the B/L solutions.
Effect of B/L solutions on acid-base homeostasis
There is a general consensus that low plasma bicarbon-
ate levels should be avoided in dialysis patients. Indeed,
acidosis is known to adversely affect protein metabolism
in chronic uremic patients [2]. In addition, observations
from animal and clinical studies suggest that metabolic
acidosis affects several organs and other physiologic func-
tions, including a depression of cardiac function and stim-
ulation of parathyroid hormone (PTH) activity [13]. It is
recommended that every effort should be made to cor-
rect metabolic acidosis because this condition has been
clearly proven to have a number of detrimental effects
[13, 14]. Many physicians use the normal plasma bicar-
bonate range as a target, but higher levels achieved with
the use of a 40 mmol/L compared to a 35 mmol/L lac-
tate solution have been reported to improve the patient’s
nutritional state [14]. Indeed, it has been found that pro-
tein breakdown is reduced at bicarbonate values around
30 mmol/L [13, 14]. Overall, a plasma bicarbonate tar-
get in the high normal range appears desirable. From a
theoretical point of view, alkalosis might be associated
with adynamic bone disease and increased soft tissue cal-
cification, but there are no clinical data in PD patients
indicating that mild alkalosis would be associated with
these effects.
A total of 59 patients who had been treated by contin-
uous ambulatory peritoneal dialysis (CAPD) for at least
3 months with a dialysis solution containing 40 mmol/L
lactate were entered into a phase II parallel, randomized,
open-label, controlled, prospective study [9, 10]. Patients
were randomized to receive dialysis with B/L 25/15 solu-
tion (N = 20), a solution containing 38 mmol/L bicarbon-
ate (N = 20), or a solution containing 40 mmol/L lactate
(control, N = 19), and followed for 2 months with an op-
tional 4-month extension. The primary efficacy variable
was the effect on plasma bicarbonate as a measure of
control of uremic acidosis. Acid-base status was assessed
from venous blood samples. All 3 solutions effectively
corrected acidosis. In the B/L 25/15 group, there was a
transient rise (1.4 mmol/L, P < 0.05) in plasma bicarbon-
ate level. Although statistically significant, this modest
rise was regarded as clinically irrelevant. The reason for
the slight rise in plasma bicarbonate is not known, but
an appealing hypothesis is that in lactate-based solutions
there is a small production of lactic acid, which occurs
to a lesser degree when a B/L solution is used [15]. In
addition, one may speculate that this rise in bicarbon-
ate could reflect anabolism, resulting in less generation
of acid, and this could in turn perhaps be due to a salu-
tary effect on systemic inflammation, improved glycemic
control, or both.
In a phase III prospective, randomized, open-label,
controlled, multicenter study, 106 PD patients were ran-
domized in a 2:1 ratio to receive dialysis for 6 months with
either B/L 25/15 (N = 70), or a standard lactate-based so-
lution containing 40 mmol/L lactate (N = 36) [16]. At the
end of the 6-month efficacy period, patients were invited
to continue for an additional 6 months on the treatment
to which they had been randomized, thus giving a full year
on treatment. A total of 57 patients (43 B/L 25/15 solu-
tion and 14 control) continued into the extension phase.
Although there was a statistically significant increase in
plasma bicarbonate, this study showed that the B/L 25/15
solution was therapeutically equivalent to the standard
lactate solution in terms of the primary efficacy end point
(i.e., the control of uremic acidosis and the overall differ-
ence in plasma bicarbonate). In addition, patients on the
B/L solutions reported improvements in nausea, appetite,
fluid control, energy levels, calmness, and experienced a
significant increase in body weight (approximately 1 kg,
P <0.05) by 6 months. This weight gain was sustained over
the long term, potentially due to increased well-being re-
sulting in increased appetite. The weight gain cannot be
explained by fluid retention, because there was a slight
increase in peritoneal net ultrafiltration in the B/L 25/15
group compared to the lactate group. Dratwa et al ana-
lyzed the same efficacy parameters in a recent study of
patients on automated PD patients, and concluded that
the advantages of B/L 25/15 can be extended to these
patients [abstract; Dratwa M, Nephrol Dial Transplant
18:212, 2003].
Another randomized, parallel, controlled, open-label,
multicenter study of CAPD patients compared the ef-
fects of the B/L 25/15 solution (N = 20) and a 35 mmol/L
lactate solution (N = 11) on venous plasma bicarbonate
level [17]. The treatment period was 3 months. During
a preceding 1-month baseline period and a post-study
follow-up, all patients received the 35 mmol/L lactate so-
lution. In patients dialyzed with B/L 25/15 solution, ve-
nous plasma bicarbonate rose by 3.1 mmol/L (CI, 1.6–4.8)
from a baseline of 23.0 mmol/L (P < 0.05 vs. lactate
solution). In addition, the number of acidotic patients
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(venous plasma bicarbonate <24 mmol/L) was signifi-
cantly lower in the B/L 25/15 solution group compared to
the lactate group at every treatment period visit. These
results indicate that the B/L 15/25 solution provides im-
proved control of acidosis compared with a 35 mmol/L
lactate-buffered solution.
Because the need for added buffer varies in the patient
population, a new solution composed of 25 mmol/L bicar-
bonate and 10 mmol/L lactate (B/L 25/10; Physioneal
35) was developed to increase therapy flexibility. Re-
cently, Otte et al [15] reported the results of a Danish-
Spanish prospective, open-label study that compared the
B/L 25/10 solution with a standard 35 mmol/L lactate so-
lution during an 8-week treatment period. In this study,
all patients used a standard 35 mmol/L lactate solution
during a 2-week baseline and a 2-week follow-up period.
Venous plasma bicarbonate levels rose from 24.4 mmol/L
when patients were on the pure lactate solution to
26.1 mmol/L when using the bicarbonate/lactate solution
(P < 0.001). When patients were using the B/L 25/10
solution, 66% of the plasma bicarbonate values were
maintained within the normal range of 24–30 mmol/L,
compared with 46.2% of values when patients were on the
pure lactate solution (P < 0.001). The authors concluded
that the B/L 25/10 solution provided better correction of
acidosis than an equivalent 35 mmol/L standard lactate
solution.
Effect of B/L solutions on ultrafiltration and small
solute clearance
The phase III prospective, randomized, open-label,
controlled, multicenter study that compared the efficacy
of a B/L 25/15 solution with that of a standard lactate so-
lution [16] also showed important results regarding other
efficacy variables, such as 24-hour ultrafiltration and peri-
toneal urea and creatinine clearances. In the B/L 25/15 so-
lution group, mean 24-hour ultrafiltration increased from
baseline by 150 mL/day (P < 0.05), and 5 patients spon-
taneously reported improved ultrafiltration; no change in
ultrafiltration was observed in the control group. The so-
lutions were shown to be therapeutically equivalent with
respect to peritoneal urea and creatinine clearances. Sim-
ilarly, the efficacy of the B/L 25/10 solution was equivalent
to that of a standard lactate solution with regard to the
peritoneal equilibration test (PET) results, adequacy, and
ultrafiltration [15].
Effect of B/L solutions on infusion pain
The pain experienced by some patients during PD in-
fusions has been attributed to the acidity of conventional
dialysis solutions [6]. Infusion pain is usually observed
in new patients commencing dialysis and is often tran-
sient in nature, spontaneously disappearing over time.
However, infusion pain can remain a troublesome com-
plication in some PD patients, potentially interfering with
compliance, and in the most extreme cases can result
in the discontinuation of PD. The most common treat-
ment to alleviate infusion pain is the neutralization of
the PD solution by manual injection of sodium bicar-
bonate into the solution immediately prior to infusion.
Although a number of reports have demonstrated the
effectiveness of such manual injection in alleviating infu-
sion pain [18, 19], the need to complete this procedure
prior to every infusion adds to the therapy burden for
the patient and also increases the overall cost of therapy.
The greatest concern, however, is the increased risk of
peritonitis due to potential external contamination of the
solution.
A randomized, double-blind, crossover study [6] exam-
ined the effects of the B/L 25/15 solution, a pure bicar-
bonate (38 mmol/L) solution, and a 40 mmol/L lactate
solution in 18 patients who had experienced repeated
inflow pain with conventional lactate (40 mmol/L) solu-
tions. Patients were evaluated during 2 dialysis exchanges
with each test solution in random order over a period of
1 to 3 weeks (i.e., each patient was assessed on 6 occa-
sions). A five-point verbal scale was used to assess pain
intensity during the infusion, dwell, and drain phases. To
assess inflow pain in a systematic way, patients completed
the validated McGill Pain Questionnaire (MPQ) after
40 minutes of the dwell.
The B/L 25/15 solution and the pure bicarbonate so-
lution significantly reduced peak pain during infusion
compared with the lactate solution (P = 0.001 for both
solutions vs. lactate). Though not statistically significant,
there was a trend for a lower pain score with the B/L
25/15 solution (peak pain response of 0.4) compared with
pure bicarbonate (peak pain response of 0.6). In addi-
tion, the peak pain score during dwell and drain was
significantly lower for B/L 25/15 compared with the bi-
carbonate solution. The MPQ produced similar results;
the B/L 25/15 and the bicarbonate solutions produced sig-
nificantly lower scores for the total weighted pain-rating
index than the control lactate solution. Again, there was
a trend for lower scores with B/L 25/15 than with bi-
carbonate. Infusion of the B/L 25/15 solution also was
associated with significantly lower scores than infusion
of lactate for the individual MPQ dimensions (affec-
tive, evaluative, sensory, miscellaneous), the number of
words chosen (which assesses pain severity), and the
present pain intensity. Importantly, for every single vari-
able, mean scores were better with B/L 25/15 than with
the pure bicarbonate solution. In a prospective random-
ized study comparing B/L 25/15 and conventional dialysis
solutions, 40% of patients receiving B/L 25/15 reported
less infusion pain/abdominal discomfort [16]. This per-
centage is substantially higher than reported earlier, sug-
gesting that the frequency of abdominal symptoms to a
large extent remains underestimated.
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In summary, bicarbonate-based, pH-neutral solutions
are effective in reducing the intensity of pain experienced
with the infusion of a conventional lactate solution. The
B/L 25/15 solution appears to be the most effective in
reducing inflow pain, possibly because of the additional
benefit of a physiologic pCO2 compared with the pure bi-
carbonate solution. Reduction in inflow pain is a valuable
clinical outcome as it has a favorable effect on quality of
life and therefore may improve patient compliance. In
addition, it indicates also improved biocompatibility.
Effect of B/L solution on immune response to infection
Preliminary findings from The European PD Solutions
Registry (PDSR) showed that the B/L 25/15 solutions
reduced the duration of peritonitis episodes [abstract;
Van Bree M et al, J Am Soc Nephrol 13:43A, 2003], and
significantly decreased the proportion of patients with
peritonitis (21%) compared with lactate solutions (29%,
P < 0.0005). The PDSR was initiated in November 1997
and is a prospective registry of patients (current cumu-
lative total, 2313) treated with alternative PD solutions.
These results may reflect a salutary effect on both local
and systemic immune response.
SAFETY PROFILE OF B/L SOLUTIONS
The phase II study described previously [9, 10] also
assessed the safety of the B/L 25/15 solution in CAPD
patients. The following safety parameters were assessed:
peritoneal permeability (using the PET), dialysis ade-
quacy, biochemical changes, and adverse events. Plasma
bicarbonate levels were not influenced of transport sta-
tus [10]. The analysis of the PET and clearances showed
that none of the PD solutions had a major impact on
membrane permeability and adequacy parameters, and
renal function was unchanged over time. The most com-
monly reported adverse events (peritonitis, hyperten-
sion, hypercalcemia, and hyperphosphatemia) were not
attributed to the test solutions. There were no statisti-
cally significant differences between the 2 groups with
regard to the numbers of patients reporting each event.
The phase III study [16] showed that safety parameters re-
mained stable over the 1-year study period. Results from
the UK/Italian multicenter study [10] also showed that
patients on the B/L 25/15 solution presented no changes
in blood biochemistry parameters measured in the PET
or with regard to adequacy of dialysis, indicating that the
solution was well tolerated. Surprisingly, in this study [10],
calcium carbonate intake did not influence plasma bicar-
bonate levels.
The new bicarbonate/lactate solutions could play an
important role in achieving adequate acid basis status.
Indeed, a recent clinical trial showed that the B/L 25/10
solution provided better correction of acidosis than an
equivalent 35 mmol/L standard lactate solution, without
any safety issues [15]. Nonetheless, the future option of
a more individualized treatment of acidosis, using both
a B/L 25/10 and a B/L 25/15 solution, may represent a
therapeutic advantage.
Another important issue was addressed by Williams
et al [20], who analyzed the effect of the B/L 25/15 solu-
tion and a standard 40 mmol/L lactate-buffered solution
on the blood glucose response of 6 stable diabetic pa-
tients when a standard dose of insulin was added to the
dialysis solution. The results showed that the blood glu-
cose levels of the patients were similar for all 3 exchanges
(lactate, B/L 25/15, lactate), and showed similar trends
over time. Thus, neither the neutral pH nor the presence
of bicarbonate appeared to influence the blood glucose
levels of diabetic patients. This implies that the bioavail-
ability of insulin and its adsorption onto the polyvinyl
chloride (PVC) bag, are unchanged by any constituents
in the B/L 25/15 solution. Therefore, it can be concluded
that insulin can be added to the B/L 25/15 solution in the
same way as for the standard lactate-based solutions.
In vitro data clearly show the superiority of B/L
25/15 solutions in preserving leukocyte and mesothelial
cell function compared with acidic lactate-buffered solu-
tions [7]. The findings are consistent with ex vivo data
from the phase II and III clinical trials, which demon-
strated that patients dialyzed with solutions containing
bicarbonate/lactate or pure bicarbonate have better-
preserved peritoneal macrophage function [assessed by
tumor necrosis factor a (TNFa) release], a marker of
improved host defense status, than patients treated with
traditional lactate-based solutions [11, 21]. Also, markers
of peritoneal mesothelial cell mass and intraperitoneal
inflammation have been assessed in patients treated con-
tinuously with either B/L 25/15 or standard solutions
[23, 24]. The results showed that when patients were di-
alyzed with B/L 25/15 solution, there was a statistically
significant decrease in interleukin (IL)-6, and hyaluronic
acid (HA), both markers of local inflammation. Given
that intraperitoneal and systemic inflammation (a well es-
tablished predictor of mortality in PD patients [24]) may
be linked to each other [abstract; Pecoits-Filho R et al,
J Am Soc Nephrol 13:42A, 2002], and that inflamma-
tion is known to be associated with changes in peri-
toneal membrane structure and function and therefore
indirectly with outcome on dialysis, the reduction
of inflammation could be of great significance in
long-term PD.
CONCLUSION
Bicarbonate/lactate-buffered PD solutions offer an ef-
fective, safe, well-tolerated, and physiologically balanced
alternative to conventional lactate-buffered solutions.
Moreover, these alternative solutions have proved to be
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Table 1. Key differences between bicarbonate/lactate solutions and
lactate-buffered solutions observed in clinical trials
Physiologic pH, pCO2,
and buffer; reduced GDP
Composition and lactate concentration
Adequacy parameters Comparable [9, 10]
Transport parameters Comparable [9, 10]
Adverse events Comparable [9, 10, 16]
Acidosis correction Improved [16]
Biocompatibility in vitro Increased cell vitality [12]
Biocompatibility in vivo Increase in CA125 [23], decrease in IL-6
and VEGF [22], hyaluronan [23]
Ultrafiltration Enhanced [16]
Peritonitis Decrease in duration and proportion of
patients [abstract; Van Bree M, J Am
Soc Nephrol 13:43A, 2003]
Infusion pain Relieved [6]
Nutritional status Improved [16]
Quality of life Improved [15]
Abbreviations are: GDP, glucose degradation products; CA125, cancer
antigen 125; IL-6, interleukin-6; VEGF, vascular endothelial growth factor.
more biocompatible based on several in vitro, ex vivo, and
in vivo studies. Randomized clinical trials have demon-
strated additional advantages including reduction in in-
fusion pain, more efficient acid-base control, increased
ultrafiltration, and reduced peritonitis duration, with
equivalent peritoneal small solutes clearances and no
changes in membrane transport parameters (Table 1).
Therefore, it can be concluded that consistent clinical data
support the use of B/L solutions as the preferred dialy-
sis fluids in future of PD, as their use may enhance the
global (local plus systemic) biocompatibility. Future clin-
ical trials will assess and quantify how these advantageous
characteristics translate into improvements in patient and
technique survival.
Reprint requests to Bengt Lindholm, M.D., Ph.D., Divisions of Bax-
ter Novum and Renal Medicine, Karolinska Institutet, K-56 Huddinge
University Hospital, S 141 86 Stockholm, Sweden.
E-mail: bengt.lindholm@klinvet.ki.se
REFERENCES
1. BERGSSTROM J: Metabolic acidosis and nutrition in dialysis patients.
Blood Purif 13:361–367, 1995
2. GRAHAM KA, REAICH D, CHANNON SM, et al: Correction of acidosis
in hemodialysis decreases whole-body protein degradation. J Am
Soc Nephrol 8:632–637, 1997
3. GRAHAM KA, HOENICH NA, GOODSHIP TH: Pre and interdialytic
acid-base balance in hemodialysis patients. Int J Artif Organs
24:192–196, 2001
4. HUTCHISON AJ, GOKAL R: Improved solutions for peritoneal dial-
ysis: Physiological calcium solutions, osmotic agents and buffers.
Kidney Int 38(Suppl):S153–159, 1992
5. SLINGENEYER A, MION C, MOURAD G, et al: Progressive scleros-
ing peritonitis: A late and severe complication of maintenance
peritoneal dialysis. Trans Am Soc Artif Intern Organs 29:633–640,
1983
6. MACTIER RA, SPROSEN TS, GOKAL R, et al: Bicarbonate and bi-
carbonate/lactate peritoneal dialysis solutions for the treatment of
infusion pain. Kidney Int 53:1061–1067, 1998
7. TOPLEY N: In vitro biocompatibility of bicarbonate-based peritoneal
dialysis solutions. Perit Dial Int 17:42–47, 1997
8. CANCARINI GC, FAICT D, DE VOS C, et al: Clinical evaluation of a
peritoneal dialysis solution with 33 mmol/L bicarbonate. Perit Dial
Int 18:576–582, 1998
9. COLES GA, GOKAL R, OGG C, et al: A randomized controlled trial
of a bicarbonate- and a bicarbonate/lactate-containing dialysis so-
lution in CAPD. Perit Dial Int 17:48–51, 1997
10. COLES GA, O’DONOGHUE DJ, PRITCHARD N, et al: A controlled trial
of two bicarbonate-containing dialysis fluids for CAPD—Final re-
port. Nephrol Dial Transplant 13:3165–3171, 1998
11. MACKENZIE RK, HOLMES CJ, MOSELEY A, et al: Bicarbonate/lactate-
and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo
peritoneal macrophage TNF-a secretion. J Am Soc Nephrol 9:1499–
1506, 1998
12. TOPLEY N, KAUR D, PETERSEN MM, et al: In vitro effects of bicarbon-
ate and bicarbonate-lactate buffered peritoneal dialysis solutions on
mesothelial and neutrophil function. J Am Soc Nephrol 7:218–224,
1996
13. STEIN A, MOORHOUSE J, ILES-SMITH H, et al: Role of an improve-
ment in acid-base status and nutrition in CAPD patients. Kidney
Int 52:1089–1095, 1997
14. WALLS J: Metabolic acidosis and uremia. Perit Dial Int 15:S36–38,
1995
15. OTTE K, GONZALEZ MT, BAJO MA, et al: Clinical experience with a
new bicarbonate (25 mmol/L)/lactate (10 mmol/L) peritoneal dial-
ysis solution. Perit Dial Int 23:138–145, 2003
16. TRANAEUS A: A long-term study of a bicarbonate/lactate-based peri-
toneal dialysis solution—Clinical benefits. The Bicarbonate/Lactate
Study Group. Perit Dial Int 20:516–523, 2000
17. CARRASCO AM, RUBIO MA, SANCHEZ TOMMERO JA, et al: Acido-
sis correction with a new 25 mmol/l bicarbonate/15 mmol/l lactate
peritoneal dialysis solution. Perit Dial Int 21:546–553, 2001
18. BUNCHMAN TE, BALLAL SH: Treatment of inflow pain by pH adjust-
ment of dialysate in peritoneal dialysis. Perit Dial Int 11:179–180,
1991
19. YAMAMOTO T, SAKAKURA T, YAMAKAWA M, et al: Clinical effects of
long-term use of neutralized dialysate for continuous ambulatory
peritoneal dialysis. Nephron 60:324–329, 1992
20. WILLIAMS P, MARIOTT J, COLES G, et al: Insulin efficacy with a new bi-
carbonate/lactate peritoneal dialysis solution. Perit Dial Int 20:467–
469, 2000
21. MACKENZIE RK, JONES S, MOSELEY A, et al: In vivo exposure to
bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis
fluids improves ex vivo peritoneal macrophage function. Am J Kid-
ney Dis 35:112–121, 2000
22. COOKER LA, LUNEBURG P, HOLMES CJ, et al: Interleukin-6 levels
decrease in effluent from patients dialyzed with bicarbonate/lactate-
based peritoneal dialysis solutions. Perit Dial Int 21(Suppl 3):S102–
107, 2001
23. JONES S, HOLMES CJ, KREDIET RT, et al: Bicarbonate/lactate-based
peritoneal dialysis solution increases cancer antigen 125 and de-
creases hyaluronic acid levels. Kidney Int 59:1529–1538, 2001
24. PECOITS-FILHO R, BARANY P, LINDHOLM B, et al: Interleukin-6 is
an independent predictor of mortality in patients starting dialysis
treatment. Nephrol Dial Transplant 17:1684–1688, 2002
